Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia

NCT00538694 ↗

Phase 3 Completed Merck & Co., Inc.

RandomizedParallel-groupDouble-blind

Summary

To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.

Timeline

Start: 2000-10-31
Primary completion: 2001-09-30
Completion: 2001-09-30

Outcome

Missed primary endpoint

paper In the intent-to-treat population, the clinical cure rate among daptomycin-treated patients with CAP was 70.9%, compared with 77.4% among ceftriaxone-treated patients PMID 18444848 ↗

paper CONCLUSIONS: Daptomycin is not effective for the treatment of CAP, including infections caused by Streptococcus pneumoniae and Staphylococcus aureus. PMID 18444848 ↗

Publications

Results Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, Thorne GM, Luperchio SA, Arbeit RD, Alder J. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008 Apr 15;46(8):1142-51. doi: 10.1086/533441.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daptomycin	Other / unclassified	4 mg/kg	Intravenous